Published in Proc Natl Acad Sci U S A on April 03, 2009
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol (2010) 1.13
Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol (2009) 1.10
Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci U S A (2010) 1.08
Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS One (2014) 1.00
Cross-presentation: how to get there - or how to get the ER. Front Immunol (2012) 0.95
The Role of FcRn in Antigen Presentation. Front Immunol (2014) 0.93
Differential use of autophagy by primary dendritic cells specialized in cross-presentation. Autophagy (2015) 0.93
Intracellular events regulating cross-presentation. Front Immunol (2012) 0.93
Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol (2014) 0.93
The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J Immunol (2011) 0.92
Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice. J Immunol (2010) 0.90
Into the intracellular logistics of cross-presentation. Front Immunol (2012) 0.90
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology (2013) 0.89
Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol (2014) 0.89
How to connect an IgE-driven response with CTL activity? Cancer Immunol Immunother (2011) 0.89
Dendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapy. PLoS One (2010) 0.88
The role of insulin-regulated aminopeptidase in MHC class I antigen presentation. Front Immunol (2012) 0.88
Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci (2012) 0.83
Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets. Front Immunol (2015) 0.83
Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape. PLoS Pathog (2015) 0.82
Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII. PLoS One (2013) 0.80
Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice. PLoS One (2014) 0.79
Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule. Oncoimmunology (2014) 0.78
Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol (2015) 0.77
Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proc Natl Acad Sci U S A (2012) 0.77
Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized. Hum Vaccin Immunother (2016) 0.76
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Mol Ther (2016) 0.76
Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Adv Exp Med Biol (2015) 0.75
Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells. Elife (2016) 0.75
The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells. Front Immunol (2017) 0.75
TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget (2016) 0.75
Evidence of an Antimicrobial Peptide Signature Encrypted in HECT E3 Ubiquitin Ligases. Front Immunol (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (1997) 5.80
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol (1999) 4.53
T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52
Use of colloidal gold particles in double-labeling immunoelectron microscopy of ultrathin frozen tissue sections. J Cell Biol (1981) 4.33
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 4.18
Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 4.12
Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med (1997) 4.04
Phagosomes are competent organelles for antigen cross-presentation. Nature (2003) 3.97
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (2007) 3.27
Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol (2008) 3.08
Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol (2003) 3.03
A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity (2006) 3.00
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
Transport of peptide-MHC class II complexes in developing dendritic cells. Science (2000) 2.62
Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A (1999) 2.17
Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J Cell Biol (2001) 1.87
Cross-priming. Nat Immunol (2006) 1.78
Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol (2005) 1.72
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med (2000) 1.56
Plumbing the sources of endogenous MHC class I peptide ligands. Curr Opin Immunol (2006) 1.47
Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol (2003) 1.38
Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol (2003) 1.29
Antigen loading of MHC class I molecules in the endocytic tract. Traffic (2001) 1.27
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol (1993) 1.20
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16
In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine (1995) 1.10
Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol (2005) 1.09
The many roads to cross-presentation. J Exp Med (2005) 1.08
A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell (2007) 6.31
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
The biogenesis and functions of exosomes. Traffic (2002) 4.49
Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem (2003) 4.14
Cryosectioning and immunolabeling. Nat Protoc (2007) 3.23
Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med (2009) 3.12
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Arabidopsis sterol endocytosis involves actin-mediated trafficking via ARA6-positive early endosomes. Curr Biol (2003) 2.84
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity (2006) 2.66
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 2.31
Cooperation of GGAs and AP-1 in packaging MPRs at the trans-Golgi network. Science (2002) 2.28
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98
Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med (2002) 1.73
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
SNX1 defines an early endosomal recycling exit for sortilin and mannose 6-phosphate receptors. Traffic (2007) 1.66
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59
C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol (2004) 1.57
CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med (2007) 1.57
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest (2006) 1.51
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Mammalian GGAs act together to sort mannose 6-phosphate receptors. J Cell Biol (2003) 1.41
Involvement of the endoplasmic reticulum in peroxisome formation. Mol Biol Cell (2003) 1.41
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med (2002) 1.39
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
Immunoelectron microscopic localization of cholesterol using biotinylated and non-cytolytic perfringolysin O. J Histochem Cytochem (2002) 1.33
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol (2009) 1.31
Peroxisomes start their life in the endoplasmic reticulum. Traffic (2003) 1.26
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood (2003) 1.18
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res (2013) 1.18
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev (2002) 1.16
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16
In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15
Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol (2005) 1.15
Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol (2002) 1.14
The conformation of neurotensin bound to its G protein-coupled receptor. Proc Natl Acad Sci U S A (2003) 1.14
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol (2012) 1.14
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
The plasticity of multivesicular bodies and the regulation of antigen presentation. Semin Cell Dev Biol (2002) 1.12
Innate immune recognition triggers secretion of lysosomal enzymes by macrophages. Traffic (2007) 1.10
Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol (2003) 1.10
Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med (2007) 1.09
C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors. J Immunol (2007) 1.08
An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc Natl Acad Sci U S A (2012) 1.08
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem (2008) 1.08
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer (2010) 1.06
MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic (2002) 1.06
Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol (2007) 1.05
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med (2009) 1.05
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 1.04
Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation (2003) 1.03
Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol (2007) 1.02
Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol (2011) 1.02
Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol (2002) 1.01
Fcγ receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1. PLoS Pathog (2010) 1.01
Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes. J Immunol (2008) 1.01
Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum (2009) 1.00
Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun (2011) 1.00
Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol (2008) 1.00
Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway. Mol Biol Cell (2002) 0.98
The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res (2006) 0.97
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol (2013) 0.96
Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol (2008) 0.96
TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem Biol (2005) 0.95
Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol (2002) 0.95
TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol (2012) 0.95
Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes. Bioorg Med Chem Lett (2007) 0.94
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer (2012) 0.94
Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci (2002) 0.94
Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol (2012) 0.94
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol (2013) 0.93